$PVCT
Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment
Thursday June 19, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.
Management will discuss the outline of the Company's planned phase 3 study of PV-10 in the treatment of melanoma and developments in the use of PV-10 in other cancer indications including PV-10 in combination as appropriate. It will also review PV-10 data presented in Chicago at ASCO earlier in the month on June 2nd, as well as provide updates on PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.
The Company has submitted PV-10 phase 2 melanoma study results to www.clinicaltrials.gov and will announce when these are published and become publicly available. In the interim, the Company is providing data presented at ASCO via this link: http://www.pvct.com/publications/ASCO-Poster-2014.pdf, which contains the phase 3 study outline that the Company will discuss on today's conference call. Moffitt Cancer Center data presented at ASCO is expected to be published in a future peer-reviewed journal publication.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 19, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for International callers, and using the Conference ID#13584727.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140619 on the Provectus website.
Provectus Biopharmaceuticals, Inc. to Hold Conference Call Today to Detail Outline of Phase 3 Clinical Trial of PV-10 in Melanoma Treatment
Thursday June 19, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, wishes to remind interested parties that it will hold a conference call today, Thursday, June 19, 2014 at 4:00 p.m. EDT.
Management will discuss the outline of the Company's planned phase 3 study of PV-10 in the treatment of melanoma and developments in the use of PV-10 in other cancer indications including PV-10 in combination as appropriate. It will also review PV-10 data presented in Chicago at ASCO earlier in the month on June 2nd, as well as provide updates on PH-10 and news regarding its use. Management will also discuss its potential plans to monetize its PV-10 and PH-10 assets with various contemplated license and co-development transactions.
The Company has submitted PV-10 phase 2 melanoma study results to www.clinicaltrials.gov and will announce when these are published and become publicly available. In the interim, the Company is providing data presented at ASCO via this link: http://www.pvct.com/publications/ASCO-Poster-2014.pdf, which contains the phase 3 study outline that the Company will discuss on today's conference call. Moffitt Cancer Center data presented at ASCO is expected to be published in a future peer-reviewed journal publication.
Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately 15 minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until August 19, 2014, and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for International callers, and using the Conference ID#13584727.
The complete press release is available at www.pvct.com/pressrelease.html?article=20140619 on the Provectus website.
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
